In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.
about
Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsLymphoma Immunotherapy: Current StatusCpG Oligonucleotides as Cancer Vaccine AdjuvantsVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Combining radiation and immunotherapy: a new systemic therapy for solid tumors?In-situ tumor vaccination: Bringing the fight to the tumorEpithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspectsSafety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.Combinations of immunotherapy and radiation in cancer therapy.Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transferTopical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaNovel therapeutic agents for cutaneous T-Cell lymphoma.Current clinical trials testing combinations of immunotherapy and radiation.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Thermosensitive Hydrogel Co-loaded with Gold Nanoparticles and Doxorubicin for Effective ChemoradiotherapyClinical opportunities in combining immunotherapy with radiation therapy.Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsSmaller Agents for Larger Therapeutic Indices: Nanoscale Brachytherapy with 177Lu-Labeled Gold Nanoparticles.Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivoEngineering nano- and microparticles to tune immunityIntratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.The Roles of Radiotherapy and Immunotherapy for the Treatment of LymphomaIntratumoral immunization: a new paradigm for cancer therapy.CpG plus radiotherapy: a review of preclinical works leading to clinical trial.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Immune modulation and stereotactic radiation: improving local and abscopal responses.The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.Pattern recognition receptors: immune targets to enhance cancer immunotherapy.In situ vaccination for the treatment of cancer.Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationVaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.
P2860
Q26746551-6EEDF4D5-7DC7-41C3-A942-EC16F924A71CQ26747695-E59203E5-F00D-48C7-BE1B-8D34BE8FC259Q26765115-F89263C4-436A-487E-8399-81DBFA9D64CEQ26782902-609EB983-91CE-4F2A-ACE4-8E09E1A8AF28Q26783826-5514A139-DCB9-4D40-BD49-2E4262A0A7EEQ26796314-A66C4649-29DB-4921-BBF4-B8BB80D070A0Q26991721-DCB4A985-645C-4B2F-B89F-8BD1BFF908FAQ26991976-9224AB7E-6B9D-47DE-89BA-755FDA701FC2Q27025290-EA2C90A3-22CC-452A-9B80-0FC5C8062987Q33413438-6456109C-5846-410E-AB43-017E65BDB9CCQ33726546-9F2AE6EF-24ED-4D59-8A53-02C9D79D6D88Q34582640-FFFA0767-793C-4B3E-A817-996CD5F8C19FQ34919077-053062A2-24EC-4E01-B699-49D7E351717FQ36070459-3E6A2328-6E07-4F26-8E08-FE29EA55D4BAQ36161365-EE0D7BCD-F8B6-459A-AB72-2465DF345C66Q36268306-FF244C25-894E-4BC4-A93A-C192523279E8Q36387028-5F9811B8-B450-434D-987C-328FC6EFD5B8Q36445146-25A817FF-1B85-43FE-B70E-F4F4AA5F9057Q36449873-720FDE3F-B57D-47FA-9A69-7A98BB92CBE7Q36675055-07399945-42EC-4A53-B9BD-DAD82DAACD5EQ36827406-B63BBD06-211C-442B-B697-EC2FF1A83BF8Q36963486-D7EE64F2-1B41-4C47-AAE9-2B2E4DD2281EQ37044950-2C0CD020-05DD-4792-9C20-D9355D56A354Q37205125-AE060E69-4DDF-4D2A-8F1E-FD6D89433520Q37469720-9F0E746A-0E7D-447E-A86C-0BAD6600B15DQ37580131-5AD32086-3915-4E48-B789-2FE0136EB188Q37640319-A21997B4-D694-4871-BD8E-838773BD4104Q37691837-B6652867-35E0-45E5-A843-7C2D5CA0A352Q38036658-46A454E1-9E04-43AD-92E9-AB3E015A78DAQ38168903-9B0987EF-1C0D-4D71-95C8-83DB342F4114Q38170122-3051C00D-3F1A-4CBF-A99E-A6F78CBE7692Q38294283-CEC8A392-062B-4D33-825D-D55E6F06240DQ38657642-A9A88BA8-8F8A-43FA-882A-10BB9AD6C038Q38666304-2E9EAFFA-784A-4BC7-B0DB-4AD843357485Q38690773-1C2E8334-7E67-44A1-A348-84773DC249C1Q38727470-5AE2D183-B2BE-4777-9AA8-8AAB95ACCB20Q38892071-BAF2BA70-F61E-423A-8FF4-DF7A04BF4691Q38974641-06430367-BB8F-4577-81A3-598B8B816CE0Q39043404-4E8869EA-9808-4887-9E38-679F1B807BAFQ39055861-8592AA47-771B-4262-9ABB-411212EE36E8
P2860
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In situ vaccination against my ...... radiation: a phase 1/2 study.
@ast
In situ vaccination against my ...... radiation: a phase 1/2 study.
@en
type
label
In situ vaccination against my ...... radiation: a phase 1/2 study.
@ast
In situ vaccination against my ...... radiation: a phase 1/2 study.
@en
prefLabel
In situ vaccination against my ...... radiation: a phase 1/2 study.
@ast
In situ vaccination against my ...... radiation: a phase 1/2 study.
@en
P2093
P2860
P1433
P1476
In situ vaccination against my ...... radiation: a phase 1/2 study.
@en
P2093
Anjali Morales
Bharathi Lingala
Cameron Harrison
Daniel Navi
Debra K Czerwinski
Farah Abdulla
Joshua D Brody
Ranjana H Advani
Richard T Hoppe
P2860
P304
P356
10.1182/BLOOD-2011-05-355222
P407
P577
2011-11-01T00:00:00Z